Abstract | BACKGROUND AND OBJECTIVE:
Pemetrexed plus platinum has shown efficacy as a first-line treatment for advanced non-small cell lung cancer (NSCLC), but little is known about its efficacy and safety in East Asian patients. We report the final analysis of overall survival (OS) from a multicentre, randomized, phase II trial in chemotherapy-naive Chinese patients with advanced NSCLC. An additional meta-analysis was performed to systematically evaluate pemetrexed/ platinum as first-line treatment for advanced NSCLC. METHODS: Eligible patients received up to six cycles of pemetrexed, 500 mg/m(2) plus cisplatin, 75 mg/m(2) (day 1) or gemcitabine, 1000 mg/m(2) (days 1 and 8) plus cisplatin, 75 mg/m(2) (day 1). OS and toxicity were assessed. RESULTS: A total of 254 patients were randomized, and 251 were eligible for inclusion in the efficacy and safety analyses. Median OS in the pemetrexed/ cisplatin arm was 15.3 months, compared with 16.9 months in the gemcitabine/ cisplatin arm [hazard ratio (HR) 1.09; 95% confidence interval (CI) 0.80-1.48; log-rank P = 0.4888). There was a trend towards improved survival in both arms. Patients in the pemetrexed/ cisplatin arm showed a lower incidence of drug-related grade 3 to 4 leukopenia and thrombocytopenia. Meta-analysis showed that pemetrexed- platinum treatment was associated with 19% longer survival among females (HR 0.81; 95% CI 0.69-0.96) and 17% longer survival among patients with non-squamous cell lung cancer (HR 0.83; 95% CI 0.73-0.95). CONCLUSIONS: In Chinese patients with advanced NSCLC, pemetrexed/ cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/ cisplatin. Meta-analysis supports the use of pemetrexed- platinum as first-line treatment for female patients and those with the non-squamous cell subtype of advanced NSCLC.
|
Authors | Xinji Zhang, Jian Lu, Jinfang Xu, Hui Li, Jingyi Wang, Yingyi Qin, Pilin Ma, Lixin Wei, Jia He |
Journal | Respirology (Carlton, Vic.)
(Respirology)
Vol. 18
Issue 1
Pg. 131-9
(Jan 2013)
ISSN: 1440-1843 [Electronic] Australia |
PMID | 22882698
(Publication Type: Clinical Trial, Phase II, Journal Article, Meta-Analysis, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2012 The Authors. Respirology © 2012 Asian Pacific Society of Respirology. |
Chemical References |
- Antimetabolites, Antineoplastic
- Glutamates
- Pemetrexed
- Deoxycytidine
- Platinum
- Guanine
- Gemcitabine
|
Topics |
- Adult
- Aged
- Antimetabolites, Antineoplastic
(administration & dosage, adverse effects, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Asia
- Carcinoma, Non-Small-Cell Lung
(drug therapy, mortality)
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Female
- Glutamates
(administration & dosage, adverse effects, therapeutic use)
- Guanine
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Humans
- Lung Neoplasms
(drug therapy, mortality)
- Male
- Middle Aged
- Pemetrexed
- Platinum
(administration & dosage, adverse effects, therapeutic use)
- Survival Analysis
- Treatment Outcome
- Gemcitabine
|